References in periodicals archive ?
Alemtuzumab is a humanised monoclonal antibody targeting the CD52 marker present on B and T lymphocytes, monocytes and macrophages.
Los anticuerpos monoclonales mas usados son aquellos contra el receptor de IL-2 (basiliximab y daclizumab) y el dirigido contra el antigeno CD52 (alemtuzumab).
Hale G (2001 ) The CD52 antigen and development of the CAMPATH antibodies.
Jiwon Oh of the division of neurology at the University of Toronto analyzed outcomes of pregnancies among women who had been treated with alemtuzumab (Lemtrada), an antibody that targets CD52.
So Qasim and colleagues used a different pair of TALENs to remove a protein called CD52 from the CAR T cells.
sup][1],[2] Alemtuzumab is a humanized mAb targeting the cell surface antigen CD52, which is expressed on more than 95% of all normal B lymphocytes, T lymphocytes, and monocytes.
Antibodies include but are not limited to HER2/neu (Epidermal Growth Factor Receptor), ER (Estrogen Receptor alpha & beta), PR (Progesterone Receptor), CD20, CD30, and CD52.
According to the company, Alemtuzumab is a monoclonal antibody that selectively targets CD52, a protein abundant on T and B cells.
In addition to CD56, plasmacytomas may aberrantly express CD117, CD20, CD52, CD10, and EMA.
It acts by targeting the surface antigen CD52 expressed on lymphocytes and monocytes resulting in lymphopaenia.
Alemtuzumab is a humanised IgG1 mAb that binds to CD52 on leucocytes, including T- and B-cells, natural killer cells, monocytes and macrophages, depleting these cells.